This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Versteeg, H. H. Articles by Ruf, W. Search for Related Content PubMed PubMed Citation Articles by Versteeg, H. H. Articles by Ruf, W.

Protease-Activated Receptor (PAR) 2, but not PAR1, Signaling Promotes the Development of Mammary Adenocarcinoma in Polyoma Middle T Mice

¹ Department of Immunology, The Scripps Research Institute; ² Department of Pathology, University of California at San Diego, La Jolla, California; ³ Sidney Kimmel Cancer Center, San Diego, California; and ⁴ Johnson & Johnson PRD, Spring House, Pennsylvania

Requests for reprints: Wolfram Ruf, Department of Immunology, SP258, The Scripps Research Institute, La Jolla, CA 92037. Phone: 858-784-2748; Fax: 858-784-8480; E-mail: ruf{at}scripps.edu.

Key Words: Breast Cancer • Coagulation • Proteases

The G protein–coupled protease-activated receptors (PAR) are key signaling components for proteases in vascular biology and tumor progression. To address the contributions of PAR1 and PAR2 to breast cancer development, we established cohorts of mouse mammary tumor virus–polyoma middle T (PyMT) PAR1^–/– and PAR2^–/– mice, considering that the PyMT model recapitulates aspects of human disease. Appearance of palpable tumors, tumor expansion, and metastasis was indistinguishable between wild-type and PAR1^–/– mice. PAR1^–/– breast cancer cells were no longer responsive to thrombin in vitro, excluding compensatory up-regulation of alternative thrombin receptors and indicating that thrombin-PAR1 signaling is dispensable in breast tumor microenvironments. In contrast, palpable tumors and multifocal disease developed slower in PAR2^–/– mice, and as a consequence of delayed tumor onset, metastasis was reduced. Analysis of early tumors showed persistence of adenomas with delayed appearance of vascularized adenocarcinomas in PAR2^–/– mice. Furthermore, CXCL1 production by early PAR2^–/– tumors was reduced. These results are consistent with previous xenograft data that implicated breast cancer PAR2 signaling in the induction of proangiogenic growth factors and chemokines. This study establishes that protease signaling contributes to mammary tumor development and that PAR2, rather than the thrombin receptor PAR1, plays a crucial role in the angiogenic switch. [Cancer Res 2008;68(17):7219–27]

This article has been cited by other articles:

				F. Schaffner and W. Ruf Tissue Factor and PAR2 Signaling in the Tumor Microenvironment Arterioscler Thromb Vasc Biol, December 1, 2009; 29(12): 1999 - 2004. [Abstract] [Full Text] [PDF]

				Y. W. van den Berg, L. G. van den Hengel, H. R. Myers, O. Ayachi, E. Jordanova, W. Ruf, C. A. Spek, P. H. Reitsma, V. Y. Bogdanov, and H. H. Versteeg Alternatively spliced tissue factor induces angiogenesis through integrin ligation PNAS, November 17, 2009; 106(46): 19497 - 19502. [Abstract] [Full Text] [PDF]

				R. S. Kasthuri, M. B. Taubman, and N. Mackman Role of Tissue Factor in Cancer J. Clin. Oncol., October 10, 2009; 27(29): 4834 - 4838. [Abstract] [Full Text] [PDF]

				E. Izumchenko, M. K. Singh, O. V. Plotnikova, N. Tikhmyanova, J. L. Little, I. G. Serebriiskii, S. Seo, M. Kurokawa, B. L. Egleston, A. Klein-Szanto, et al. NEDD9 Promotes Oncogenic Signaling in Mammary Tumor Development Cancer Res., September 15, 2009; 69(18): 7198 - 7206. [Abstract] [Full Text] [PDF]

				M. M. Fluck and B. S. Schaffhausen Lessons in Signaling and Tumorigenesis from Polyomavirus Middle T Antigen Microbiol. Mol. Biol. Rev., September 1, 2009; 73(3): 542 - 563. [Abstract] [Full Text] [PDF]